• Users Online: 165
  • Print this page
  • Email this page
Year : 2022  |  Volume : 5  |  Issue : 1  |  Page : 11-18

Outcome of COVID-19 on Indian patients with cancer: A multicenter, retrospective study

1 Departments of Medical Oncology, Dr GVN Cancer Institute, Tiruchirappalli, Tamil Nadu, India
2 Meenakshi Mission Hospital and Research Center, Madurai, Tamil Nadu, India
3 Madras Cancer Care Foundation, Chennai, Tamil Nadu, India
4 Mangalore Institute of Oncology, Mangaluru, Karnataka, India
5 Department of Hematology, Apollo Hospital, Bengaluru, Karnataka, India
6 Columbia Asia Hospital, Bengaluru, Karnataka, India
7 Manipal Hospital, Vijayawada, Andhra Pradesh, India
8 Department of Surgical Oncology, Silverline Speciality Hospital, Tiruchirappalli, Tamil Nadu, India
9 Department of Psycho Oncology, Fenivi Research Solutions, Chennai, Tamil Nadu, India

Correspondence Address:
Arun Seshachalam
M.D., D.M., Head of Dept.of Medical Oncology, Dr GVN Cancer Institute, 46, Near Super Bazar, Singarathope, Tiruchirappalli, Tamil Nadu – 620 008; Associate. Prof. Dept. Of Medical Oncology, Dhanalakshimi Srinivasan Medical College, Keelakanavai - Siruvachur Rd, Perambalur, Tamil Nadu - 621 212
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/crst.crst_212_21

Rights and Permissions

Background: Managing patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic has been challenging. Disruptions in cancer management have been observed due to cancellation of treatment, issues related to commuting, and dearth of health-care workers. Objectives: This study was conducted during the first wave of the COVID-19 pandemic and was aimed at evaluating the 30-day all-cause mortality among patients with cancer and COVID-19 infection and the factors affecting it. Materials and Methods: In this retrospective study, we collected secondary data from nine tertiary care centers in South India over a period of 10 months from March to Dec 2020. Patients across all age groups with histopathologically confirmed diagnosis of cancer who were affected by COVID-19 during their evaluation or treatment were included in the study. The primary outcome variables of the present study were 30-day all-cause mortality, cancer outcomes, and COVID-19 outcomes. Results: A total of 206 patients were included. Median age of the cohort was 55.5 years, and the male-to-female ratio was 1:1.03. The 30-day mortality rate was 12.6%. Twenty-two patients (10.7%) had severe COVID-19 infection at the initial presentation. Predictors for severe pneumonia at the initial presentation were incomplete remission at the time of COVID-19 diagnosis and palliative intent of treatment. Severe pneumonia at the initial presentation, diagnosis of COVID-19 on or before August 2020, and need for ventilator support were associated with increased mortality. Conclusion: Severity of infection at the initial presentation, cancer status, and the intent of cancer treatment impact COVID-19 outcomes in patients with cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal